AAAAAA
Results: 1-25/40
Authors:
MOLLER P
MAEHLE L
HEIMDAL K
DORUM A
APOLD J
ENGEBRETSEN LF
KAURIN RM
JORGENSEN OG
HELGERUD P
QVIST H
BJORNDAL H
KULLMANN G
BOHLER P
NYSTED A
SOREIDE JA
VARHAUG JE
AAS T
FJOSNE HE
HAGEN A
DUE J
KARESEN R
FORMOE E
MALME PA
STEDJEBERG JO
SVENNINGSEN SS
STENEHJEM E
KOLNES J
VERHAGE CCH
HARAM S
RONNING GA
WASMUTH H
HAMMELBO S
JACOBSEN U
TRONNES S
GIERCKSKY KE
TROPE C
KVINNSLAND S
Citation: P. Moller et al., PROSPECTIVE FINDINGS IN BREAST-CANCER KINDREDS - ANNUAL INCIDENCE RATES ACCORDING TO AGE, STAGE AT DIAGNOSIS, MEAN SOJOURN TIME, AND INCIDENCE RATES FOR CONTRALATERAL CANCER, Breast, 7(1), 1998, pp. 55-59
Authors:
MARTH C
TROPE C
VERGOTE IB
KRISTENSEN GB
Citation: C. Marth et al., 10-YEAR RESULTS OF A RANDOMIZED TRIAL COMPARING CISPLATIN WITH CISPLATIN AND CYCLOPHOSPHAMIDE IN ADVANCED, SUBOPTIMALLY DEBULKED OVARIAN-CANCER, European journal of cancer, 34(8), 1998, pp. 1175-1180
Authors:
TROPE C
KAERN J
Citation: C. Trope et J. Kaern, MANAGEMENT OF BORDERLINE TUMORS OF THE OVARY - STATE-OF-THE-ART, Seminars in oncology, 25(3), 1998, pp. 372-380
Authors:
SMITHSORENSEN B
KAERN J
HOLM R
DORUM A
TROPE C
BORRESENDALE AL
Citation: B. Smithsorensen et al., THERAPY EFFECT OF EITHER PACLITAXEL OR CYCLOPHOSPHAMIDE COMBINATION TREATMENT IN PATIENTS WITH EPITHELIAL OVARIAN-CANCER AND RELATION TO TP53 GENE STATUS, British Journal of Cancer, 78(3), 1998, pp. 375-381
Authors:
AABO K
ADAMS M
ADNITT P
ALBERTS DS
ATHANAZZIOU A
BARLEY V
BELL DR
BIANCHI U
BOLIS G
BRADY MF
BRODOVSKY HS
BRUCKNER H
BUYSE M
CANETTA R
CHYLAK V
COHEN CJ
COLOMBO N
CONTE PF
CROWTHER D
EDMONSON JH
GENNATAS C
GILBEY E
GORE M
GUTHRIE D
KAYE SB
LAING AH
LANDONI F
LEONARD RC
LEWIS C
LIU PY
MANGIONI C
MARSONI S
MEERPOHL H
OMURA GA
PARMAR MKB
PATER J
PECORELLI S
PRESTI M
SAUERBREI W
SKARLOS DV
SMALLEY RV
SOLOMON HJ
STEWART LA
STURGEON JFG
TATTERSALL MHN
WHARTON JT
HUININK WWT
TOMIROTTI M
TORRI W
TROPE C
TURBOW MM
VERMORKEN JB
WEBB MJ
WILBUR DW
WILLIAMS CJ
WILTSHAW E
YEAP BY
Citation: K. Aabo et al., CHEMOTHERAPY IN ADVANCED OVARIAN-CANCER - 4 SYSTEMATIC METAANALYSES OF INDIVIDUAL PATIENT DATA FROM 39 RANDOMIZED TRIALS, British Journal of Cancer, 78(11), 1998, pp. 1479-1487
Authors:
MARTH C
SORHEIM N
KAERN J
TROPE C
Citation: C. Marth et al., TAMOXIFEN IN THE TREATMENT OF RECURRENT OVARIAN-CARCINOMA, International journal of gynecological cancer, 7(4), 1997, pp. 256-261
Authors:
BJORGE T
ENGELAND A
HANSEN S
TROPE C
Citation: T. Bjorge et al., OVARIAN-CANCER - ARE WE MAKING PROGRESS, European journal of cancer, 33, 1997, pp. 621-621
Authors:
TROPE C
KAERN J
KRISTENSEN G
ROSENBERG P
SORBE B
Citation: C. Trope et al., PACLITAXEL IN UNTREATED FIGO STAGE-III SUBOPTIMALLY RESECTED OVARIAN-CANCER, Annals of oncology, 8(8), 1997, pp. 803-806
Authors:
KRISTENSEN GB
TROPE C
Citation: Gb. Kristensen et C. Trope, EPITHELIAL OVARIAN-CARCINOMA, Lancet, 349(9045), 1997, pp. 113-117
Authors:
TROPE C
KRISTENSEN G
Citation: C. Trope et G. Kristensen, CURRENT STATUS OF CHEMOTHERAPY IN GYNECOLOGIC CANCER, Seminars in oncology, 24(5), 1997, pp. 1-22
Authors:
SUNDFOR K
LYNG H
KONGSGARD U
TROPE C
ROFSTAD EK
Citation: K. Sundfor et al., POLAROGRAPHIC MEASUREMENT OF PO(2) IN CERVIX CARCINOMA, Gynecologic oncology, 64(2), 1997, pp. 230-236
Authors:
SCHEISTROEN M
TROPE C
KAERN J
PETTERSEN EO
ALFSEN GC
NESLAND JM
Citation: M. Scheistroen et al., DNA-PLOIDY AND EXPRESSION OF P53 AND C-ERBB-2 IN EXTRAMAMMARY PAGETS-DISEASE OF THE VULVA, Gynecologic oncology, 64(1), 1997, pp. 88-92
Authors:
BLOMLIE V
ROFSTAD EK
TROPE C
LIEN HH
Citation: V. Blomlie et al., CRITICAL SOFT-TISSUES OF THE FEMALE PELVIS - SERIAL MR-IMAGING BEFORE, DURING, AND AFTER RADIATION-THERAPY, Radiology, 203(2), 1997, pp. 391-397
Authors:
SKOMEDAL H
KRISTENSEN GB
ABELER VM
BORRESENDALE AL
TROPE C
HOLM R
Citation: H. Skomedal et al., TP53 PROTEIN ACCUMULATION AND GENE MUTATION IN RELATION TO OVEREXPRESSION OF MDM2 PROTEIN IN OVARIAN BORDERLINE TUMORS AND STAGE-I CARCINOMAS, Journal of pathology, 181(2), 1997, pp. 158-165
Authors:
MARTH C
ZEIMET AG
WIDSCHWENDTER M
LUDESCHER C
KAERN J
TROPE C
GASTL G
DAXENBICHLER G
DAPUNT O
Citation: C. Marth et al., PACLITAXEL-DEPENDENT AND DOCETAXEL-DEPENDENT ACTIVATION OF CA-125 EXPRESSION IN HUMAN OVARIAN-CARCINOMA CELLS, Cancer research, 57(17), 1997, pp. 3818-3822
Authors:
MARTH C
WIDSCHWENDTER M
KAERN J
JORGENSEN NP
WINDBICHLER G
ZEIMET AG
TROPE C
DAXENBICHLER G
Citation: C. Marth et al., CISPLATIN RESISTANCE IS ASSOCIATED WITH REDUCED INTERFERON-GAMMA-SENSITIVITY AND INCREASED HER-2 EXPRESSION IN CULTURED OVARIAN-CARCINOMA CELLS, British Journal of Cancer, 76(10), 1997, pp. 1328-1332
Authors:
DORUM A
ABELER VM
HEIMDAL K
TROPE C
MOLLER P
Citation: A. Dorum et al., THE PROBLEM OF SKIPPED GENERATION AND SUBCLINICAL DISEASE IN FAMILIALBREAST-OVARIAN CANCER, Acta obstetricia et gynecologica Scandinavica, 76(2), 1997, pp. 166-168
Authors:
TROPE C
KAERN J
Citation: C. Trope et J. Kaern, PROGNOSIS AND MANAGEMENT OF BORDERLINE TUMORS OF THE OVARY, Current opinion in obstetrics & gynecology, 8(1), 1996, pp. 12-16
Authors:
MOLLER P
MAEHLE L
HEIMDAL K
DORUM A
TRETLI S
HELGERUD P
QUIST H
BJORNDAL H
KARESEN R
NYSTED A
VARHAUG JE
FJOSNE HE
GULENG RJ
DUE J
BOHLER P
GIERCKSKY KE
TROPE C
KVINNSLAND S
Citation: P. Moller et al., INHERITED BREAST-CARCINOMA - PROSPECTIVE FINDINGS IN 1194 WOMEN AT RISK, Acta oncologica, 35, 1996, pp. 7-11
Authors:
TROPE C
ANDERSSON H
BJORKHOLM E
FRANKENDAL B
HIMMELMAN A
HOGBERG T
HORVATH G
PETTERSON B
PERSSON H
RYBERG M
SIMONSEN E
SORBE B
STENDAHL U
WESHOLM B
Citation: C. Trope et al., DOXORUBICIN-MELPHALAN WITH AND WITHOUT CISPLATIN IN ADVANCED OVARIAN-CANCER - 10-YEAR SURVIVAL RESULTS FROM A PROSPECTIVE RANDOMIZED STUDY BY THE SWEDISH COOPERATIVE OVARIAN-CANCER STUDY-GROUP, Acta oncologica, 35, 1996, pp. 109-118
Authors:
SCHEISTROEN M
TROPE C
KAERN J
ABELER VM
PETTERSEN EO
KRISTENSEN GB
Citation: M. Scheistroen et al., MALIGNANT-MELANOMA OF THE VULVA FIGO STAGE-I - EVALUATION OF PROGNOSTIC FACTORS IN 43 PATIENTS WITH EMPHASIS ON DNA-PLOIDY AND SURGICAL-TREATMENT, Gynecologic oncology, 61(2), 1996, pp. 253-258
Authors:
KAERN J
TROPE C
SUNDFOER K
KRISTENSEN GB
Citation: J. Kaern et al., CISPLATIN 5-FLUOROURACIL TREATMENT OF RECURRENT CERVICAL-CARCINOMA - A PHASE-II STUDY WITH LONG-TERM FOLLOW-UP/, Gynecologic oncology, 60(3), 1996, pp. 387-392
Authors:
LYNG H
SUNDFOR K
TROPE C
ROFSTAD EK
Citation: H. Lyng et al., OXYGEN-TENSION AND VASCULAR DENSITY IN HUMAN CERVIX CARCINOMA, British Journal of Cancer, 74(10), 1996, pp. 1559-1563
Authors:
RAJU KS
KING RJB
KAERN J
SUMNER D
ABELER VM
MANDALAYA S
TROPE C
Citation: Ks. Raju et al., INFLUENCE OF HSP27 AND STEROID-RECEPTOR STATUS ON PROVERA SENSITIVITY, DNA-PLOIDY AND SURVIVAL OF FEMALES WITH ENDOMETRIAL CANCER, International journal of gynecological cancer, 5(2), 1995, pp. 94-100
Authors:
KRISTENSEN GB
BAEKELANDT M
VERGOTE IB
TROPE C
Citation: Gb. Kristensen et al., A PHASE-II STUDY OF CARBOPLATIN AND HEXAMETHYLMELAMINE AS INDUCTION CHEMOTHERAPY IN ADVANCED OVARIAN-CARCINOMA (AOC), European journal of cancer, 31A, 1995, pp. 505-505